Результаты поиска

Scleredema in a Patient with AIDS-Related Lipodystrophy Syndrome.

Scleredema is a form of cutaneous mucinosis caused by an increased accumulation of collagen and mucin in the dermis. It is characterized by diffused, nonpitting swelling and induration of the skin. Scleredema diabeticorum is one type of scleredema associated with diabetes mellitus. AIDS-related insulin resistance and lipodystrophy syndrome are a newly emerging entities in HIV-infected patients associated with severe metabolic disturbances and insulin resistance. The long-standing diabetes in these patients may contribute to the development of scleredema diabeticorum. Here, we report the rare o

Совпадение в полном тексте источника
… He had been taking efavirenz, emtricitabine, and tenofovir for the last 5 years. He was treated of diabetes mellitus and dyslipidemia. He also had coronary artery disease status postpercutaneous coronary intervention. …

When to investigate for secondary hyperhidrosis: data from a retrospective cohort of all causes of recurrent sweating.

Background: Identification of underlying diseases is crucial for secondary hyperhidrosis management, but data are lacking to guide appropriate investigation.Objective: To describe aetiologies of recurrent sweating in a hospital setting and the diagnostic performance parameters of their respective clinical/biological features.Patients and Methods: We performed a monocentric evaluative study in a tertiary care centre. Patients with recurrent generalised sweating were selected via the Clinical Data Warehouse (CDW) by screening all electronic hospital documents from the year 2018 using a keyword-b

Совпадение в полном тексте источника
… Triptorelin a | Anti-estrogenic action Aromatase inhibitor | 2 | Letrozole a , Exemestane c | Anti-estrogenic action Estrogen receptor modulators | 1 | Tamoxifen b | Anti-estrogenic action Hormonal contraception | 1 | Ethinylestradiol + Levonorgestrel c | Antiretroviral | 1 | Emtricitabine + Rilpivirine + Tenofovir … Infliximab | 1 | Adalimumab | 1 | Ixekizumab | 1 | Sunitinib | 1 | Chemotherapy (unspecified) | 1 | Cyproterone acetate | 1 | Ethinylestradiol + Levonorgestrel | 1 | Enantone + Abiraterone | 1 | Exemestane | 1 | Tamoxifen | 1 | Letrozole | 1 | Triptorelin | 1 | Emtricitabine + Rilpivirine + Tenofovir …

Infectious Diseases

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Pharmacological treatments of COVID-19.

The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and

Совпадение в полном тексте источника
… Emtricitabine/tenofovir Tenofovir is a DNA synthesis inhibitor and approved as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor. … It has been suggested that tenofovir could be a potential drug candidate for SARS-CoV2 pulmonary disease, although the clinical effectiveness of this drug has not yet been evidenced for SARS-CoV2 [ 71 ]. …

Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

To ensure the safety of high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT), evidence-based recommendations on infectious complications after HDC/ASCT are given. This guideline not only focuses on patients with haematological malignancies but also addresses the specifics of HDC/ASCT patients with solid tumours or autoimmune disorders. In addition to HBV and HCV, HEV screening is nowadays mandatory prior to ASCT. For patients with HBs antigen and/or anti-HBc antibody positivity, HBV nucleic acid testing is strongly recommended for 6 months after HDC/ASCT or for the durati

Совпадение в полном тексте источника
… Today, tenofovir and entecavir are antiviral substances with resistance rates of 1–5%. Their prophylactic administration is safe even in combination with most of the conditioning regimens [ 79 , 80 ]. … AGIHO strongly recommends the use of either tenofovir or entecavir in patients with HBsAg- and/or anti-HBc positivity. Patients should regularly be monitored for reactivation despite antiviral prophylaxis by HBV DNA measurements. …

Муриновая корреляция саркомы Эпштейна-Барра и саркомы Капози (MHV-68) представляет собой ценную модель для оценки чувствительности к антивирусным препаратам и взаимодействия в комбинаторных наркотиках.

Человеческие герпесвирусы представляют собой основные человеческие патогены. Особый интерес представляют члены подсемейства < < Герпесвирина > > , поскольку они вызывают хронические заболевания, такие, как рак, изменяя клеточные процессы и вводя клетки отдыха в непрерывно расширяющуюся фазу. Кроме того, в центре внимания постоянно находятся аутоиммунные заболевания, такие, как множественный склероз. Прототипический вирус человека - герпесвирус - вирус Эпштейна - Барра (ЭБВ) оказался трудно проанализировать в целях развития противовирусной терапии из-за проблем, связанных с распрост

Совпадение в полном тексте источника
… Moreover, the new experimental reference inhibitor of EBV replication, tenofovir alafenamide, was added to the study (TAF, MedChemExpress, Monmouth Junction, NJ, USA). Stock solutions of all compounds were prepared at a 10 mM concentration in sterile DMSO (Sigma Aldrich, St. … Table 2 Comparing MHV-68, EBV and HCMV in their sensitivity to selected antiviral drugs [µM] a . a For virus systems and antiviral readouts see Materials and methods; TAF, tenofovir alafenamide; n.d., not determined. …

AGA Clinical Practice Update on Pregnancy-Related Gastrointestinal and Liver Disease: Expert Review.

DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update is to review the availabl … evel >200,000 IU/mL during the third trimester of pregnancy should be considered for treatment with tenofovir disoproxil fumarate. BEST PRACTICE ADVICE 13: In patients on immunosuppressive therapy for chronic liver diseases or after liver transplantation, therapy should be continued at the lowest effective dose during pregnancy. Mycophenolate mofetil should …

Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.

BACKGROUND: There are few data assessing the uptake of first-line dolutegravir among men and women living with HIV in low-income and middle- … RT was 3·9 years (2·0-6·4) years, with most people receiving efavirenz (178 624 [98·7%] people) and tenofovir (178 148 [98·4%]). By Feb 28, 2022, 121 174 (67·0%) of 180 956 people had transitioned to first-line dolutegravir at a median of 283 days (IQR 203-526). In a univariable Cox regression model the hazard of being transitioned to dolutegravir was lower …

Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.

BACKGROUND: Islatravir is a nucleoside reverse transcriptase translocation inhibitor in development for the treatment and prevention of HIV- … doravirine (100 mg) and lamivudine (300 mg) or to doravirine (100 mg) plus lamivudine (300 mg) plus tenofovir disoproxil fumarate (TDF; 300 mg) once daily with placebo (part 1). Treatment groups were stratified according to screening HIV-1 RNA concentration (≤100 000 copies per mL or >100 000 copies per mL). After at least 24 weeks of treatment, participant …

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.

BACKGROUND: Despite satisfactory efficacy of WHO-recommended second-line antiretroviral treatment for patients with HIV in low-income countr … 12, and every 3 months until 96 weeks; if viral load exceeded 500 copies per mL at any visit, NRTI (tenofovir and lamivudine) were reintroduced into treatment. The primary outcome was the proportion of participants who had treatment failure at 96 weeks in the intention-to-treat analysis, where treatment failure was defined as one of the following: a confirm …

Hepatitis B Gene Therapy Coming to Age.

The major pandemics caused by chronic viral infections is produced by HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV), with estima … during gene therapy, which have never been seen using the most potent polymerase inhibitors (i.e., tenofovir or entecavir). Finally, unanticipated significant reductions in cccDNA are seen with HBV gene therapy, most likely as prove of an indirect benefit of waning the immunosuppressive effect of large over amounts of HBsAg released by infected hepatocytes …

An Update in Drug-Induced Thrombotic Microangiopathy.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Moreover, for the first time an antiretroviral treatment of human immunodeficiency virus consisting of tenofovir/emtricitabine was found to have a causality relationship with immune TTP ( 83 ). … antibodies | Hematology/Oncology/ Rheumatology Cocaine/ Ecstasy Oxymorphone/Oxycodone Polyethylene oxide (PEO) | Opioids / Drugs of abuse | Toxicology Interferon beta 1-a /1-b Alemtuzumab Fingolimod | Disease modifying treatments for Multiple Sclerosis | Neurology Valproic acid | Anticonvulsive | Tenofovir …

Solitary Hepatic Plasmacytoma With IgM Monoclonal Gammopathy: A Case Report.

Solitary extramedullary plasmacytoma (SEP) is a rare plasma cell neoplasm that typically arises in the upper aerodigestive tract but may occur in other organs, including the liver. IgM-secreting SEPs are exceedingly rare and can be challenging to differentiate from other lymphomas with similar presentations. We report a case of a 73-year-old female who presented with fatigue and cytopenias, later found to have a large hepatic mass. Biopsy revealed a kappa-restricted plasma cell neoplasm with strong CD138, BCL2, CD20, and PAX5 expression and absence of MYD88 L265P mutation via immunohistochemis

Совпадение в полном тексте источника
… Zanubrutinib was discontinued, and tenofovir was added. Of note, the patient's EBV IgG testing was positive. She was discharged to an acute rehabilitation facility, and she passed away shortly after. 3. Discussion SEPs are rare entities, representing < 5% of plasma cell dyscrasias [ 3 ]. …

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.

In December 2019, a novel SARS-CoV-2 coronavirus emerged, causing an outbreak of life-threatening pneumonia in the Hubei province, China, and has now spread worldwide, causing a pandemic. The urgent need to control the disease, combined with the lack of specific and effective treatment modalities, call for the use of FDA-approved agents that have shown efficacy against similar pathogens. Chloroquine, remdesivir, lopinavir/ritonavir or ribavirin have all been successful in inhibiting SARS-CoV-2 in vitro. The initial results of a number of clinical trials involving various protocols of administr

Совпадение в полном тексте источника
… Other nucleotide analogs, which are under investigation for their potential effectiveness against SARS-CoV-19 include triazavirin, emtricitabine, and tenofovir ( Table 1 ) ( Lythgoe and Middleton, 2020 ). … Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis. Virol. J. 2018;15(1) doi: 10.1186/s12985-018-1050-3. p. 139-139. Lythgoe M.P., Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol. …

Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis B Virus Infections.

Hepatitis B virus (HBV) infections affect approximately 296 million people around the world, and the prevalence of any past or present HBV infection during the years 2015-2018 was as high as 4.3%. Acute HBV infection often presents with nonspecific symptoms and is usually self-limited, but 5% of patients can have persistent infections leading to chronic HBV infection and the risk of turning into chronic HBV infection is significantly higher in babies with vertical transmission (95%). Patients with chronic HBV infection are usually asymptomatic, but 15 to 40% of chronic HBV carriers develop cir

Совпадение в полном тексте источника
… The medications and management used in the treatment include: (1) antiviral therapy with nucleoside analogs (Entecavir and Tenofovir) that remain the first-line treatment for HBV-associated cryoglobulinemia, with the goal of suppressing HBV replication and are commonly used in mild to moderate disease … The patient received IVIG along with tenofovir disoproxil fumarate 300 mg/day orally for 5 days but deteriorated with worsening respiratory symptoms requiring tracheostomy associated with persistent elevation of liver enzymes. …

Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… It is mandatory to screen lymphoma patients for HBV serology and administer antiviral prophylaxis in case of HBsAg positivity; if possible, entecavir or tenofovir must be preferred over lamivudine (less risk of resistance), and treatment should not be interrupted until 12–18 months after the end of anti-lymphoma … High Rates of Renal Tubular Damage in HBV Monoinfected Patients Long-Term Treated with Tenofovir: A Cross-Sectional, Single Center, Real-Life Study in 414 Patients J. Hepatol. 2017 66 S689 10.1016/S0168-8278(17)31851-2 67. Anderson H. Scarffe J.H. Sutton R.N. Hickmott E. Brigden D. Burke C. …

The Role of the Research Advanced Practice Provider in CAR T-Cell Clinical Trials.

In recent years, chimeric antigen receptor (CAR) T-cell therapy has emerged as an effective and potentially paradigm-shifting therapy for patients with refractory lymphoma and myeloma. This novel therapy involves engineering T cells to recognize specific antigens on the surface of cancer cells. Several CAR T-cell products are approved by the US Food and Drug Administration as a result of numerous clinical trials. Due to the complexity of these studies and the high level of care required for CAR T-cell therapy patients, the role of the research advanced practice provider (APP) has become increa

Совпадение в полном тексте источника
… hepatitis B) | Entecavir 0.5 mg orally daily | Start 2 weeks prior to cell infusion; stop 12–24 months post infusion | Adjust dose for renal function Monitor HBV titer once a month while on prophylaxis and monthly for 1 year after stopping Consult ID if entecavir cannot be given or PCR undetectable | Tenofovir … disoproxil fumarate 300 mg orally daily, OR Tenofovir alafenamide 25 mg orally daily Bacterial prophylaxis (neutropenia with ANC < 1.0 K/μ L that is expected to last ≥ 7 days) | Levofloxacin 500 mg orally or IV daily | Start cell infusion day and continue until ANC > 0.5 K/mL for 3 consecutive days …

Primed for global coronavirus pandemic: Emerging research and clinical outcome.

The global effort to combat and contain the coronavirus disease 2019 (COVID-19) caused by the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now proceeding on a war footing. The world was slow to react to the developing crisis, but once the contours of the impending calamity became evident, the different state and non-state actors have raced to put their act together. The COVID-19 pandemic has blatantly exposed the shortcomings of our healthcare system and the limitations of medical science, despite considerable advances in recent years. To effectively tack

Совпадение в полном тексте источника
… S.N. | Drug | Institute/Country | Clinical Trials | Mechanism 1 | Truvada (emtricitabine, 1 and tenofovir, 2 ) | Plan Nacionalsobre el Sida (PNS) and Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, China | Phase-II NCT04334928 ( ClinicalTrials.gov ) ChiCTR2000029468 (ICTPR … Molecular docking studies suggest that ribavirin, sofosbuvir ( 26 ), galidesivir ( 16 ), setrobuvir ( 109 ), IDX-184 ( 110 ), and tenofovir ( 2 ) tightly bind to the SARS-CoV-2 RdRp and can thus serve as potential candidates for drug repurposing studies against COVID-19 [ 112 ]. …

Hypophosphatemic rickets: diagnosis and treatment.

Hypophosphatemicrickets (HR) represents a heterogeneous group of disorders characterized by renal phosphate wasting, impaired bone mineralization, and skeletal deformities. This narrative review provides an overview of phosphate homeostasis and the molecular mechanisms underlying HR, focusing on the role of Fibroblast Growth Factor 23 (FGF23) in regulating renal phosphate use and vitamin D metabolism. The clinical, biochemical, and genetic features of both FGF23-dependent and -independent forms of HR are discussed, including X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic

Совпадение в полном тексте источника
… Also Tenofovir Disoproxil Fumarate (TDF), a common antiretroviral for HIV, has been strongly associated with proximal tubulopathy, characterized by phosphate wasting, proteinuria, and progressive kidney injury ( 89 ) . … Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36(8):1070–1073. doi: 10.1086/368314.. 90. Hong CD, Hanenson IB, Lerner S, Hammond PB, Pesce AJ, Pollak VE. …